On December 27 local time, Daiichi Sankyo announced that the targeted TROP2 antibody-drug conjugate (ADC) DATROWAY (datopotamab deruxtecan) jointly developed with AstraZeneca has been approved in Japan for the treatment of adult patients with unresectable or recurrent breast cancer who are HR-positive and HER2-negative (IHC 0, IHC 1+, or IHC 2+/ISH-) after chemotherapy.
第一三共德达博妥单抗在日本获批治疗乳腺癌
Daiichi Sankyo's datopotamab deruxtecan has been approved in Japan for the treatment of breast cancer.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated